Announcements & Press Releases

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2024. "We are excited by the momentum we're building across our innovation...

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced that management will host a conference call Thursday, November 7, 2024, at 4:30 p.m. Eastern Time to review 2024 third quarter results. To...

An automated platform designed to fight against Sepsis and Antimicrobial Resistance (AMR) Enables rapid, automated microbial identification on the Bruker MALDI Biotyper® CA System directly from...

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter ended June 30, 2024. "During the quarter we completed our pre-clinical trial demonstrating...

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in vitro diagnostics in microbiology, announced the successful completion of its WAVE pre-clinical trial. The Accelerate WAVE...

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced that management will host a conference call today, Thursday, August 8, 2024, at 4:30 p.m. Eastern Time to review 2024 second quarter results....

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial preliminary results for the first quarter ended March 31, 2024. "During the quarter we installed our first pre-clinical trial...

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time to review 2024 first quarter results....

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and year ended December 31, 2023. "In 2023, we made significant progress with the development...

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, March 28, 2024, at 4:30 p.m. Eastern Time to review 2023 fourth quarter and...

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) (the "Company") today announced the pricing of an underwritten public offering consisting of 6,860,659 units, each consisting of one share of common...

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) (the "Company") today announced the launch of a proposed underwritten public offering of 4,500,000 units, each consisting of one share of common stock...

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs through the rapid...

Working together to bring rapid, automated microbial identification directly from positive blood culture samples TUCSON, Ariz., Nov. 27, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:...

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2023. "During the quarter we made significant advances with our Wave...

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, November 9, 2023, at 4:30 p.m. Eastern Time to review 2023 third quarter...

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2023. "Throughout the quarter, we've significantly advanced our...

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, August 10, 2023, at 4:30 p.m. Eastern Time to review 2023 second quarter...

Accelerate Diagnostics, Inc., (NASDAQ: AXDX) (the "Company") a leading provider of innovative rapid diagnostic solutions, announced that it will conduct a reverse stock split of its outstanding...

Accelerate Diagnostics, Inc., (NASDAQ: AXDX) a leading provider of innovative rapid diagnostic solutions, has closed the transactions contemplated by the previously announced restructuring support...

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the first quarter for the period ended March 31, 2023. "Our first quarter results are in line with expectations,...

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, May 11, 2023, at 4:30 p.m. Eastern Time to review 2023 first quarter results....

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and year ended December 31, 2022. "In 2022, we achieved another year of revenue growth thanks...

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Wednesday, March 29, 2023, at 4:30 p.m. Eastern Time to review 2022 fourth quarter and...

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) a leading provider of innovative rapid diagnostic solutions, announced today that Steve Reichling will be stepping down as Chief Financial Officer (CFO),...

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) a disruptor in bloodstream infection identification and susceptibility testing today announced the appointment of Hany Massarany to chairman of the...

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced that the Company has submitted a 510(k) application to the FDA for Gram-negative menu expansion and breakpoint updates for the...

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter for the period ended September 30, 2022. "Our third quarter results were generally in line with...

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Monday, November 14, 2022, at 4:30 p.m. Eastern Time to review 2022 third quarter...

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) ("Accelerate Diagnostics") today announced the pricing of an underwritten public offering of 17,500,000 shares of its common stock at a price to the...

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) ("Accelerate Diagnostics") today announced that it has commenced an underwritten public offering of shares of its common stock. Accelerate Diagnostics...

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2022. "In addition to a solid quarter, I am pleased to announce...

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Monday, August 15, 2022, at 4:30 p.m. Eastern Time to review 2022 second quarter results....

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that Chief Executive Officer, Jack Phillips, will present at the 42nd Annual William Blair Growth Stock Conference on Thursday, June 7,...

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the first quarter for the period ended March 31, 2022. "First quarter financial results were consistent with our...

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Monday, May 16, 2022, at 4:30 p.m. Eastern Time to review 2022 first quarter results. To...

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and full year ended December 31, 2021. Jack Phillips, Chief Executive Officer of Accelerate...

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Wednesday, March 8, 2022, at 4:30 p.m. Eastern Time to review 2021 fourth quarter and...

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that the company is scheduled to present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on...

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced preliminary financial results for the quarter and year ending December 31, 2021. Highlights for the fourth quarter and full-year 2021...

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) announced today that it was honored as a recipient of China's Suzhou Industrial Park's (SIP) 15th Science and Technology Leaders Innovation Award for...

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) announced today that the company is scheduled to present at the 40th Annual J. P. Morgan Healthcare Conference on January 13, 2022, at 9:45a.m. Eastern....

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced the publication of its Improving Outcomes and Antibiotic Stewardship (IOAS) Study in the journal Clinical Infectious Diseases. The...

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced preliminary financial results for the third quarter for the period ended September 30, 2021, which remain subject to quarter end closing...

Accelerate Diagnostics, Inc. announced today that management will host a conference call on Tuesday, November 9, 2021, at 4:30 p.m. Eastern Time to review 2021 third quarter financial results. To...

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 2.50% Convertible Senior Notes...

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2021. "Second quarter and year to date financial results were...

Accelerate Diagnostics, Inc. announced today that management will host a conference call on Thursday, August 5, 2021, at 4:30 p.m. Eastern Time to review 2021 second quarter financial results. To...

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that it will have 3 data presentations from its Improving Outcomes and Antibiotic Stewardship (IOAS) Study at the European Congress of...